Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Kronos Bio, Inc. (KRON) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Abstract titled “A First-In-Human Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of Tolerability and Clinical Activity.”"
08/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023"
05/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023"
04/24/2023 8-K Quarterly results
03/27/2023 8-K Quarterly results
03/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023"
01/26/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure  Interactive Data
11/08/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Kronos Bio, Inc. Compensation Committee of the Board of Directors or Representative"
02/24/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022"
12/06/2021 8-K Quarterly results
11/29/2021 8-K Other Events  Interactive Data
11/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/09/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results Company today announces progression of two discovery programs within its pipeline"
08/12/2021 8-K Quarterly results
06/23/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
01/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/07/2020 8-K Other Events
11/18/2020 8-K Quarterly results
Docs: "Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia"
10/14/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy